-
1
-
-
24944512442
-
The theoretical basis of the sanocrysin treatment of tuberculosis
-
Moellgaard H. The theoretical basis of the sanocrysin treatment of tuberculosis. Br Med J 1925;1: 643-47. 10.1136/bmj.1.3353.643 20771993
-
(1925)
Br Med J
, vol.1
, pp. 643-647
-
-
Moellgaard, H.1
-
2
-
-
85083453058
-
The gold treatment of tuberculosis
-
The gold treatment of tuberculosis. Br Med J 1925;1: 668. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2226411/pdf/brmedj05703-0025.pdf20772016
-
(1925)
Br Med J
, vol.1
, pp. 668
-
-
-
3
-
-
72849171445
-
Severe infectious mononucleosis treated with chloroquine phosphate
-
Gothberg LA. Severe infectious mononucleosis treated with chloroquine phosphate. J Am Med Assoc 1960;173: 53-7. 10.1001/jama.1960.73020190016012 13851408
-
(1960)
J Am Med Assoc
, vol.173
, pp. 53-57
-
-
Gothberg, L.A.1
-
4
-
-
0014104484
-
Infectious mononucleosis treated with chloroquine. A double-blind study of 40 cases
-
Updike SJ, Eichman PL. Infectious mononucleosis treated with chloroquine. A double-blind study of 40 cases. Am J Med Sci 1967;254: 69-70. 10.1097/00000441-196707000-00008 6027689
-
(1967)
Am J Med Sci
, vol.254
, pp. 69-70
-
-
Updike, S.J.1
Eichman, P.L.2
-
5
-
-
85017454955
-
Antiviral activity of cationic amphiphilic drugs
-
Salata C, Calistri A, Parolin C, Baritussio A, Palu G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther 2017;15: 483-92. 10.1080/14787210.2017.1305888 28286997
-
(2017)
Expert Rev Anti Infect Ther
, vol.15
, pp. 483-492
-
-
Salata, C.1
Calistri, A.2
Parolin, C.3
Baritussio, A.4
Palu, G.5
-
6
-
-
25444508979
-
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
-
Vincent MJ, Bergeron E, Benjannet S, etal . Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2: 69. 10.1186/1743-422X-2-69 16115318
-
(2005)
Virol J
, vol.2
, pp. 69
-
-
Vincent, M.J.1
Bergeron, E.2
Benjannet, S.3
-
7
-
-
84873712360
-
Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
-
Yan Y, Zou Z, Sun Y, etal . Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013;23: 300-2. 10.1038/cr.2012.165 23208422
-
(2013)
Cell Res
, vol.23
, pp. 300-302
-
-
Yan, Y.1
Zou, Z.2
Sun, Y.3
-
8
-
-
85034590476
-
Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis
-
Shiryaev SA, Mesci P, Pinto A, etal . Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. Sci Rep 2017;7: 15771. 10.1038/s41598-017-15467-6 29150641
-
(2017)
Sci Rep
, vol.7
, pp. 15771
-
-
Shiryaev, S.A.1
Mesci, P.2
Pinto, A.3
-
9
-
-
85016471291
-
Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells
-
Li X, Burton EM, Bhaduri-McIntosh S. Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells. PLoS Pathog 2017;13: E1006249. 10.1371/journal.ppat.1006249 28249048
-
(2017)
PLoS Pathog
, vol.13
, pp. e1006249
-
-
Li, X.1
Burton, E.M.2
Bhaduri-McIntosh, S.3
-
10
-
-
85031102693
-
Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice
-
Li C, Zhu X, Ji X, etal . Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017;24: 189-94. 10.1016/j.ebiom.2017.09.034 29033372
-
(2017)
EBioMedicine
, vol.24
, pp. 189-194
-
-
Li, C.1
Zhu, X.2
Ji, X.3
-
11
-
-
84955603527
-
Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model
-
Dowall SD, Bosworth A, Watson R, etal . Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 2015;96: 3484-92. 10.1099/jgv.0.000309 26459826
-
(2015)
J Gen Virol
, vol.96
, pp. 3484-3492
-
-
Dowall, S.D.1
Bosworth, A.2
Watson, R.3
-
12
-
-
84929431373
-
Lack of protection against ebola virus from chloroquine in mice and hamsters
-
Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H. Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis 2015;21: 1065-7. 10.3201/eid2106.150176 25988934
-
(2015)
Emerg Infect Dis
, vol.21
, pp. 1065-1067
-
-
Falzarano, D.1
Safronetz, D.2
Prescott, J.3
Marzi, A.4
Feldmann, F.5
Feldmann, H.6
-
13
-
-
85047499799
-
Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection
-
Roques P, Thiberville SD, Dupuis-Maguiraga L, etal . Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018;10: 268. 10.3390/v10050268 29772762
-
(2018)
Viruses
, vol.10
, pp. 268
-
-
Roques, P.1
Thiberville, S.D.2
Dupuis-Maguiraga, L.3
-
14
-
-
84929170755
-
Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery
-
Wang LF, Lin YS, Huang NC, etal . Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res 2015;35: 143-56. 10.1089/jir.2014.0038 25321315
-
(2015)
J Interferon Cytokine Res
, vol.35
, pp. 143-156
-
-
Wang, L.F.1
Lin, Y.S.2
Huang, N.C.3
-
15
-
-
84879572897
-
Chloroquine use improves dengue-related symptoms
-
Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz 2013;108: 596-9. 10.1590/S0074-02762013000500010 23903975
-
(2013)
Mem Inst Oswaldo Cruz
, vol.108
, pp. 596-599
-
-
Borges, M.C.1
Castro, L.A.2
Fonseca, B.A.3
-
16
-
-
80051819215
-
Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial
-
Paton NI, Lee L, Xu Y, etal . Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011;11: 677-83. 10.1016/S1473-3099(11)70065-2 21550310
-
(2011)
Lancet Infect Dis
, vol.11
, pp. 677-683
-
-
Paton, N.I.1
Lee, L.2
Xu, Y.3
-
17
-
-
0020625123
-
Disposition of chloroquine in man after single intravenous and oral doses
-
Gustafsson LL, Walker O, Alván G, etal . Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983;15: 471-9. 10.1111/j.1365-2125.1983.tb01532.x6849784
-
(1983)
Br J Clin Pharmacol
, vol.15
, pp. 471-479
-
-
Gustafsson, L.L.1
Walker, O.2
Alván, G.3
-
18
-
-
84979009448
-
Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity
-
Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct 2016;34: 191-6. 10.1002/cbf.3182 27001679
-
(2016)
Cell Biochem Funct
, vol.34
, pp. 191-196
-
-
Akpovwa, H.1
-
19
-
-
85080879659
-
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
-
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14: 72-3. 10.5582/bst.2020.01047 32074550
-
(2020)
Biosci Trends
, vol.14
, pp. 72-73
-
-
Gao, J.1
Tian, Z.2
Yang, X.3
-
20
-
-
85083382067
-
Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. Version 2
-
03.22.20040758. [Preprint.]
-
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. Version 2. medRxiv 2020.03.22.20040758. [Preprint.] 10.1101/2020.03.22.20040758
-
(2020)
MedRxiv
-
-
Chen, Z.1
Hu, J.2
Zhang, Z.3
-
21
-
-
85083468005
-
Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)
-
Yan D, Zhang Z. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19). Chinese Clinical Trials Registry. http://www.chictr.org.cn/showproj.aspx? proj=48880
-
Chinese Clinical Trials Registry
-
-
Yan, D.1
Zhang, Z.2
-
22
-
-
85088375128
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial
-
Gautret P, Lagier JC, Parola P, etal . Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020: 105949. 10.1016/j.ijantimicag.2020.105949 32205204
-
Int J Antimicrob Agents
, vol.2020
, pp. 105949
-
-
Gautret, P.1
Lagier, J.C.2
Parola, P.3
-
23
-
-
85082979529
-
Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence
-
Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020;369: M1335. 10.1136/bmj.m1335 32238355
-
(2020)
BMJ
, vol.369
, pp. m1335
-
-
Lenzer, J.1
-
25
-
-
0034820122
-
Fatal toxic epidermal necrolysis associated with hydroxychloroquine
-
Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 2001;26: 457-8. 10.1046/j.1365-2230.2001.00857-3.x11488840
-
(2001)
Clin Exp Dermatol
, vol.26
, pp. 457-458
-
-
Murphy, M.1
Carmichael, A.J.2
-
26
-
-
0028325972
-
Fulminant hepatic failure secondary to hydroxychloroquine
-
Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994;35: 569-70. 10.1136/gut.35.4.569 8175002
-
(1994)
Gut
, vol.35
, pp. 569-570
-
-
Makin, A.J.1
Wendon, J.2
Fitt, S.3
Portmann, B.C.4
Williams, R.5
-
27
-
-
85083451996
-
The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin
-
04.02.20047050. [Preprint]
-
Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv 2020.04.02.20047050. [Preprint] 10.1101/2020.04.02.20047050v1
-
(2020)
MedRxiv
-
-
Chorin, E.1
Dai, M.2
Shulman, E.3
-
28
-
-
59849098808
-
Survival after massive hydroxychloroquine overdose
-
Gunja N, Roberts D, McCoubrie D, etal . Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care 2009;37: 130-3. 10.1177/0310057X0903700112 19157361
-
(2009)
Anaesth Intensive Care
, vol.37
, pp. 130-133
-
-
Gunja, N.1
Roberts, D.2
McCoubrie, D.3
-
29
-
-
84959338530
-
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature
-
Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med 2016;14: 10. 10.1186/s12916-016-0553-2 26843061
-
(2016)
BMC Med
, vol.14
, pp. 10
-
-
Onakpoya, I.J.1
Heneghan, C.J.2
Aronson, J.K.3
|